Knee osteoarthritis Market: Epidemiology, Therapies, Companies, DelveInsight | Centrexion Therapeutics, Pfizer, Eli Lilly, Ampio Pharmaceuticals, Galapagos NV, Cytonics, Flexion Therapeutics

Knee osteoarthritis therapies, such as CINGAL, DUROLANE, GELSYN-3, and others, are expected to boost the Knee osteoarthritis Market in the upcoming years.

DelveInsight has launched a new report on "Knee osteoarthritis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Knee osteoarthritis, historical and forecasted epidemiology as well as the Knee osteoarthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Knee osteoarthritis market report @ https://www.delveinsight.com/report-store/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Knee osteoarthritis Market Report:

The knee osteoarthritis (OA) market in the seven major markets (7MM) was valued at approximately USD 14.4 billion in 2023. The condition is more common in females, who account for about 60% of cases, compared to 40% in males.
When broken down by severity, mild cases represented the largest share across the 7MM. Currently, there is no standardized laboratory test to confirm the diagnosis of knee OA.
In May 2024, Organogenesis reported positive topline results from a Phase III randomized controlled trial assessing the safety and effectiveness of ReNu for treating knee OA symptoms.
Present treatment options include NSAIDs, opioids, intra-articular corticosteroids, and hyaluronic acid injections. The future market is expected to expand, driven by the anticipated launch of new therapies from companies such as Taiwan Liposome Company (TLC599), Centrexion Therapeutics (CNTX-4975), and Biosplice Therapeutics (Lorecivivint), alongside a growing patient population.
In 2023, the United States reported the highest number of knee osteoarthritis cases, totaling approximately 18,499,200, with Japan ranking second. The condition was more prevalent among females compared to males. Within the U.S., the age group 70 and above had the largest number of cases, while the 18-39 age group had the fewest cases during the same year.
On November 28, 2024, the U.S. FDA completed its 30-day review of Paradigm Biopharmaceuticals' Phase III clinical trial protocol for Zilosul (a repurposed form of pentosan polysulfate sodium) for the treatment of knee osteoarthritis, allowing the trial to proceed in Q1 of calendar year 2025.
Earlier, on September 6, 2024, Sun Pharma and Moebius Medical announced that the FDA granted Fast Track designation to their investigational therapy MM-II (a formulation of large liposomes containing DPPC and DMPC) for knee osteoarthritis pain, with Phase III trials currently in preparation.
Key Knee osteoarthritis companies such as Centrexion Therapeutics, Pfizer, Eli Lilly, Ampio Pharmaceuticals, Galapagos NV, Cytonics, Flexion Therapeutics, and others are evaluating new drugs for Knee osteoarthritis to improve the treatment landscape.
Promising Knee osteoarthritis therapies include CINGAL, DUROLANE, GELSYN-3, and others.

Knee osteoarthritis Overview

Knee osteoarthritis (OA), often referred to as degenerative joint disease, is primarily caused by gradual wear and tear leading to the progressive breakdown of articular cartilage. It is most frequently seen in older adults. The condition is classified into primary and secondary types and can impact all three compartments of the knee-the medial, lateral, and patellofemoral joints. Typically, knee OA develops slowly over a period of 10 to 15 years, eventually hindering everyday activities.

Knee osteoarthritis Market Outlook

At present, a variety of pharmacological treatments are available to manage knee osteoarthritis (OA)-related pain and improve joint function. Commonly used medications include nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroids, intra-articular hyaluronic acid, and opioids. Among these, NSAIDs have traditionally been the most widely used; however, their prolonged use-especially in older patients with multiple health conditions-is limited due to risks of gastrointestinal, kidney, heart, and blood-related side effects.

Two anti-inflammatory drugs with similar effects are celecoxib and etoricoxib, which belong to the COX-2 inhibitor class (also called coxibs). These can be taken orally or applied topically as a gel or cream directly to the affected joint. Promising new NSAIDs and COX-2 inhibitors in development for knee OA include HP-5000 and AMZ-001.

Discover how the Knee osteoarthritis market is rising in the coming years @ https://www.delveinsight.com/sample-request/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Marketed Knee Osteoarthritis Drugs
CINGAL: Anika Therapeutics
DUROLANE: Bioventus
Knee osteoarthritis Emerging Drugs
TLC599: Taiwan Liposome Company
CNTX-4975: Centrexion Therapeutics

Scope of the Knee osteoarthritis Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Knee osteoarthritis Companies: Centrexion Therapeutics, Pfizer, Eli Lilly, Ampio Pharmaceuticals, Galapagos NV, Cytonics, Flexion Therapeutics, and others
Key Knee osteoarthritis Therapies: CINGAL, DUROLANE, GELSYN-3, and others
Knee osteoarthritis Therapeutic Assessment: Knee osteoarthritis current marketed and Knee osteoarthritis emerging therapies
Knee osteoarthritis Market Dynamics: Knee osteoarthritis market drivers and Knee osteoarthritis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Knee osteoarthritis Unmet Needs, KOL's views, Analyst's views, Knee osteoarthritis Market Access and Reimbursement

To know what's more in our Knee osteoarthritis report, visit https://www.delveinsight.com/report-store/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Knee osteoarthritis Market Report:
Knee osteoarthritis market report covers a descriptive overview and comprehensive insight of the Knee osteoarthritis Epidemiology and Knee osteoarthritis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Knee osteoarthritis market report provides insights into the current and emerging therapies.
The Knee osteoarthritis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Knee osteoarthritis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Knee osteoarthritis market.

Got queries? Click here to know more about the Knee osteoarthritis market Landscape https://www.delveinsight.com/sample-request/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Knee osteoarthritis Patient Share (%) Overview at a Glance
5. Knee osteoarthritis Market Overview at a Glance
6. Knee osteoarthritis Disease Background and Overview
7. Knee osteoarthritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Knee osteoarthritis
9. Knee osteoarthritis Current Treatment and Medical Practices
10. Unmet Needs
11. Knee osteoarthritis Emerging Therapies
12. Knee osteoarthritis Market Outlook
13. Country-Wise Knee osteoarthritis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Knee osteoarthritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Knee osteoarthritis Market Outlook 2034 https://www.delveinsight.com/report-store/knee-osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Knee osteoarthritis Pipeline Insights, DelveInsight

"Knee osteoarthritis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Knee osteoarthritis market. A detailed picture of the Knee osteoarthritis pipeline landscape is provided, which includes the disease overview and Knee osteoarthritis treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.